Evogliptin Set For First Launch, In Crowded Korean Market
This article was originally published in PharmAsia News
Dong-A ST's new type 2 diabetes therapy Suganon (evogliptin) has been approved in South Korea where it is set to compete with a number of already marketed DPP-4 inhibitors in an increasingly crowded sector. The domestic approval follows global licensing out deals for the drug in the past few years in other markets including China, India, Brazil and Russia.
Register for our free email digests: